JP2025503096A5 - - Google Patents

Info

Publication number
JP2025503096A5
JP2025503096A5 JP2024543372A JP2024543372A JP2025503096A5 JP 2025503096 A5 JP2025503096 A5 JP 2025503096A5 JP 2024543372 A JP2024543372 A JP 2024543372A JP 2024543372 A JP2024543372 A JP 2024543372A JP 2025503096 A5 JP2025503096 A5 JP 2025503096A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
radioactive nuclide
composite according
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/051355 external-priority patent/WO2023139203A1/en
Publication of JP2025503096A publication Critical patent/JP2025503096A/ja
Publication of JP2025503096A5 publication Critical patent/JP2025503096A5/ja
Pending legal-status Critical Current

Links

JP2024543372A 2022-01-21 2023-01-20 がんの処置および撮像のための複合体 Pending JP2025503096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22152725.2 2022-01-21
EP22152725 2022-01-21
PCT/EP2023/051355 WO2023139203A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Publications (2)

Publication Number Publication Date
JP2025503096A JP2025503096A (ja) 2025-01-30
JP2025503096A5 true JP2025503096A5 (cg-RX-API-DMAC7.html) 2026-03-11

Family

ID=79927204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543372A Pending JP2025503096A (ja) 2022-01-21 2023-01-20 がんの処置および撮像のための複合体

Country Status (6)

Country Link
US (1) US20250099631A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503096A (cg-RX-API-DMAC7.html)
CN (1) CN118891066A (cg-RX-API-DMAC7.html)
AU (1) AU2023208408A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023139203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3498308T3 (da) 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid
CN121534209A (zh) * 2018-09-28 2026-02-17 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂,其作为显像剂和药剂用于治疗表达psma的癌症的用途

Similar Documents

Publication Publication Date Title
Nishijima et al. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy
Kaplan et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation
Lane et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F (ab') 2 antibodies
Rousseau et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
Anderson et al. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223
Cederkrantz et al. Absorbed doses and risk estimates of 211At-MX35 F (ab') 2 in intraperitoneal therapy of ovarian cancer patients
Kao et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile
Behr et al. High‐dose myeloablative radioimmunotherapy of mantle cell non‐hodgkin lymphoma with the iodine‐131–labeled chimeric anti‐CD20 antibody C2B8 and autologous stem cell support.[THIS ARTICLE HAS BEEN RETRACTED] Results of a pilot study
JP2005532262A5 (cg-RX-API-DMAC7.html)
Arazi et al. The treatment of solid tumors by alpha emitters released from 224Ra-loaded sources—internal dosimetry analysis
Ferro-Flores et al. Pharmacokinetics and dosimetry of 188Re-pharmaceuticals
JP2020528059A5 (cg-RX-API-DMAC7.html)
Rowlinson et al. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration
Ramírez-Nava et al. Hybrid (2D/3D) dosimetry of radiolabeled gold nanoparticles for sentinel lymph node detection in patients with breast cancer
Narwadkar et al. Clinical Internal dosimetry and biodistribution of 177Lu-DOTA-trastuzumab in HER2-positive metastatic and locally advanced breast carcinoma
Riva et al. Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies
Milner et al. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours
Banerjee et al. Radiation and radioisotopes for human healthcare applications
Akgun et al. Therapeutic applications of radiopharmaceuticals: an overview
Maier et al. Comparative immuno-Cerenkov luminescence and-PET imaging enables detection of PSMA+ tumors in mice using 64Cu-radiolabeled monoclonal antibodies
Riva et al. Radioimmunotherapy of CMS Malignant Gliomas by Direct Intralesional Injection of Specific 131| Radiolabeled Monoclonal Antibodies
McQuarrie et al. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients
Zhukovsky et al. Dose coefficients for monoclonal antibodies and antibody fragments labeled by zirconium-89
Stabin The importance of patient-specific dose calculations in nuclear medicine
JP2025503096A (ja) がんの処置および撮像のための複合体